BioHandler Secures Nearly RMB 1 Billion in Series A Funding Led by Bilingxing Ventures and Hillhouse Capital

Shanghai Hanzandi Life Technology Co., Ltd.(hereinafter referred to as “Hanzandi”) announced the completion of its first round of financing, amounting to nearly RMB 100 million。This round of financing was led byProxima Capital and GL VenturesCo-led the investment round.

Hanzandi is dedicated to the development of high-throughput and automated instruments and systems, providing end-to-end intelligent solutions for the life sciences and the broader health industry. Since its inception, the company has delivered comprehensive automation, intelligence, and digitalization solutions to the life sciences sector, ranging from workflow automation on simple benchtop platforms to fully automated solutions capable of handling complex steps in large-scale system applications.

Addressing the pain points of growing labor demands and throughput limitations, Hansi has innovatively integrated laboratory hardware, software, and consumables into a unified platform, achieving intelligent end-to-end coordination across diverse scenarios. Compared with traditional laboratory systems, Hansi delivers higher efficiency and more stable experimental results in various life science applications, including molecular diagnostics, clinical testing, small- and large-molecule drug screening, cell line development, and molecular screening. The platform has already been deployed among numerous key opinion leader (KOL) clients.

Hanzandi Standardized Standalone PlatformCovering the CANTUS Screen high-throughput liquid handling workstation, CANTUS Flex flexible multi-channel liquid handling workstation, NEMO full-featured liquid handling workstation, VOLA nucleic acid extractor, and ARCO high-precision microliter dispenser, our cost-effective products serve nearly 100 research institutes and pharmaceutical companies.

Hanzandi Intelligent Automation Integration Platform: Providing Customers with Flexible, Modular Customized Solutions and Application PlansThese include an automated mass spectrometry analysis and processing system, an all-in-one NGS library preparation system, an automated cell line development system, an automated viral nucleic acid detection system, an automated single-cell omics library preparation system, an ultra-high-throughput viral sample extraction and molecular testing platform, a high-throughput automated drug discovery and screening platform, and a high-throughput synthetic biology automated screening and testing platform. The HanZanDi team boasts extensive experience in providing automation solutions for the life sciences industry and strong execution capabilities, earning recognition from research institutions, pharmaceutical companies, and clinical testing laboratories.

A well-known laboratory delivered by the companyHigh-Throughput Automated Solutions for Protein Drug Discovery and Screening, the entire line adopted the company's core standalone automated liquid handling workstations and a fully intelligent, end-to-end automation solution, significantly reducing customers' operational costs. To meet customers' urgent system delivery requirements,The project was successfully completed from negotiation to final delivery in less than six months, setting the industry record for the fastest delivery of a system of comparable scale. It also stands as the largest single integrated platform delivered as a turnkey project by a Chinese brand enterprise to date.

Proxima Capital and GL Ventures Backed HanZanDi Life Sciences in Its Nearly RMB 100 Million Series A Financing; The Founding Team’s Professional Background Was One of the Key Reasons for Their Investment.

The founding core team members of Hanzandi possess over a decade of experience in life science product development and a strong background in biology. They have deep expertise in life science marketing management and business model innovation, and hold numerous core patented technologies. Adhering to an ultimate innovative design philosophy centered on modularity, intelligence, and simplicity, they design and develop intelligent products with independent intellectual property rights. By integrating superior resources, Hanzandi provides end-to-end premium products and services to the global life science community.Hanzandi enables seamless dialogue with scientists through a unified language of life sciences, accurately translating and transforming life science needs to realize its vision of “becoming the pioneer in intelligent end-to-end solutions for life sciences” and fulfill its mission of “letting technology celebrate life and delivering on the promise of science.”

The completion of this financing will accelerate Handi’s in-depth strategic layout across its core standardized standalone platforms for import substitution, its intelligent automation integration platform, and its OEM/ODM platform for customized instruments and systems.

Zhao Jibin, Chairman and Founder of HanzandiHe stated, “HanZanDi’s receipt of support from two top-tier life science investors, Proxima Capital and GL Ventures, in this round of financing is a significant endorsement of the company’s technology. Both institutions have invested in and laid out a substantial portfolio of excellent upstream and downstream enterprises in the life sciences sector. Their joint investment in HanZanDi will provide the company with a robust entrepreneurial ecosystem, further drive HanZanDi’s independent, disruptive innovation, and accelerate its differentiated development path of ‘Standing Out by Being Different.’”

Li Zhe, Partner at Proxima CapitalProxima Capital stated that it continues to closely monitor the application of global innovative technologies in the fields of life sciences and healthcare. It has strategically invested across the life sciences industry chain, covering frontier life science tools and platform companies such as single-cell capture and spatial omics analysis platforms, high-throughput antibody drug screening platforms, and AI-enabled innovative biopharmaceutical R&D platforms. Industrial automation is profoundly influencing and transforming the life sciences industry. Compared with traditional manual operations, it enables ultra-high-throughput experimental procedures and drug screening, while significantly enhancing R&D efficiency and substantially reducing costs. The HanZanDi team possesses extensive experience and implementation capabilities in life sciences automation, having participated in the design of multiple ultra-high-throughput drug discovery and screening platforms and achieved breakthroughs in core standalone equipment areas. Its products and systems have served top-tier research institutes and institutions in China. Proxima Capital remains firmly optimistic about the breakthrough applications of automation and intelligent technologies in the life sciences sector. It will assist HanZanDi in integrating into Proxima’s innovation ecosystem, helping the company rapidly consolidate and expand its presence in the life sciences automation field to become an industry leader.

Project Lead, GL Ventures“The Hanzandi team possesses extensive experience in the life sciences industry and forward-looking strategic thinking. By innovatively applying industrial 5G and artificial intelligence algorithms, the team has addressed the challenges of intelligent automation in life sciences, achieving breakthrough progress and establishing comprehensive end-to-end solutions for numerous life science application scenarios. The company’s products, platforms, and services have gained recognition from many well-known domestic clients and are currently being mass-produced and delivered. GL Ventures remains firmly optimistic about Hanzandi’s leading layout and breakthrough advancements in intelligent automation within the life sciences sector, and is committed to supporting the rapid growth of Hanzandi’s business.”

Proxima Capital is a specialized investment firm focused on innovative medical technologies and disruptive biotechnologies, dedicated to serving exceptional innovative healthcare technology companies with significant growth potential. Managed and operated by a professional team with extensive experience in the medical industry, Proxima Capital boasts diverse and international expertise, professional backgrounds, and industry networks, and currently manages multiple RMB and USD funds. The firm has established a leading healthcare entrepreneurship ecosystem, facilitating connections between its portfolio companies and high-quality clinical and industrial resources, thereby achieving remarkable experience and results.

GL Ventures is Hillhouse’s venture capital platform dedicated to early-stage innovative companies, covering key sectors such as hard technology, software, biotechnology, new materials, emerging brands, and consumer tech. GL Ventures seeks out all entrepreneurs who are passionate about technology and believe in innovation. We aim to be the first call for founders seeking financing, and we look forward to accompanying them throughout their entrepreneurial journey.

Shanghai BioHandler Life Science Technology Co., Ltd., abbreviated as BioHandler, is a leading high-tech enterprise in China engaged in the research and development, manufacturing, sales, and service of intelligent automated equipment and system solutions for life sciences and medical diagnostics.

The founding core team members of HanZandi boast over a decade of experience in life science product development and strong backgrounds in biology. They possess deep expertise in life science marketing management and business model innovation, and hold numerous core patented technologies. Adhering to an ultimate innovative design philosophy characterized by modularity, intelligence, and simplicity, they design and develop intelligent products with independent intellectual property rights. By integrating superior resources, HanZandi provides exceptional products and services for the entire global life science workflow. HanZandi communicates with scientists in a unified life science language, accurately translating and transforming life science needs, thereby realizing its vision of “becoming the leader in intelligent solutions for the entire life science workflow” and fulfilling its mission to “let technology celebrate life and fulfill the promise of science.”

Guided by the organizational competencies of “passion, innovation, collaboration, learning agility, independent judgment, and altruism,” and underpinned by the methodological values of “first-principles thinking and structured reasoning,” Hanzandi embodies the ethos of “simplifying the known and exploring the unknown” and “excelling through distinctiveness.” Committed to independent innovation and dedicated to revitalizing China’s national industries, Hanzandi aims to fundamentally reshape global market dynamics, elevate the global reputation of Chinese creation, and establish itself as a premier international brand.